ImmunityBio Shares Surge 41.9% Following EU Approval for Bladder Cancer Therapy

ImmunityBio (IBRX) shares skyrocketed by 41.9% after the company secured conditional marketing authorization from the European Union for its bladder cancer therapy. The regulatory approval covers the combination of Anktiva and BCG, marking a significant milestone for the biotechnology firm. This expansion increases the company's global footprint to 33 countries, opening up substantial commercial opportunities across the European market. Investors reacted positively to the news, viewing the EU's decision as a validation of ImmunityBio's clinical approach and long-term growth potential. The therapy targets specific types of bladder cancer, addressing a critical unmet need in the oncology sector. Market analysts suggest that this approval serves as a major catalyst for future revenue generation and strengthens the company's competitive position globally.